CD274 and glioma: Fortunately, even though no immune checkpoint inhibitors have been approved for glioma (24), the efficacy of PD-1/PD-L1 inhibitors has been validated in preclinical glioma models; PD-1/PD-L1 inhibitors have been shown to restore antitumor T-cell activity and improve survival, which provides a theoretical basis for clinical trials (45–50).